Skip to main content
. 2020 Mar 2;12(4):e11177. doi: 10.15252/emmm.201911177

Figure 2. OC cell lines and patient‐derived cells undergo an EphA2 phosphorylation switch upon platinum treatment.

Figure 2

  • A, B
    EphA2 (total and phosphorylated at S897 or Y588) in OVCAR3, OVCAR4, and OVCAR8 after treatment with 0–20 μM cisplatin for 72 h was assessed by immunoblotting (A) and quantified for pS897/pY588 ratio (B). N = 4.
  • C
    EphA2 (total and phosphorylated) in corresponding untreated cells. The same β‐actin detection for these samples is shown in Appendix Fig S1B.
  • D
    Cytotoxicity assay results after cell treatment with 0–20 μM cisplatin for 72 h. N = 6.
  • E
    Quantitative assessment of EphA2 (total and phosphorylated) and pS897/pY588 ratio in early passage patient‐derived HGSC cultures treated with 0–20 μM cisplatin for 72 h (see immunoblots in Appendix Fig S2A). N = 6 patients, pooled.
  • F
    Corresponding EphA2 pS897/pY588 ratios for individual patient cells.
  • G, H
    EphA2 (total and phosphorylated) in OVCAR4 and OVCAR8 after treatment with 0–80 μM carboplatin for 72 h (G) along with pS897/pY588 quantification (H). N = 3.
Data information: In (B, D–E, and H), data are presented as mean (SD). *P < 0.05, **P < 0.01, ***P < 0.001. Exact P‐values are provided in Appendix Table S10, Student's t‐test.Source data are available online for this figure.